Evidence map›Paper›PMID 39287866›Full record

ReviewAdvances in experimental medicine and biology2024

MicroRNAs as Epigenetic Regulators of Obesity.

Ayse Basak Engin, Atilla Engin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Insulin Resistance and Inflammation.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ayse Basak EnginFaculty of Pharmacy, Department of Toxicology, Gazi University, Hipodrom, Ankara, Turkey. abengin@gmail.com.
Atilla EnginFaculty of Medicine, Department of General Surgery, Gazi University, Besevler, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In obesity, the process of adipogenesis largely determines the number of adipocytes in body fat depots. Adipogenesis is regulated by several adipocyte-selective micro-ribonucleic acids (miRNAs) and transcription factors that modulate adipocyte proliferation and differentiation. However, some miRNAs block the expression of master regulators of adipogenesis. Since the specific miRNAs display different expressions during adipogenesis, in mature adipocytes and permanent obesity, their use as biomarkers or therapeutic targets is feasible. Upregulated miRNAs in persistent obesity are downregulated during adipogenesis. Moreover, some of the downregulated miRNAs in obese individuals are upregulated in mature adipocytes. Induction of adipocyte stress and hypertrophy leads to the release of adipocyte-derived exosomes (AdEXs) that contain the cargo molecules, miRNAs. miRNAs are important messengers for intercellular communication involved in metabolic responses and have very specific signatures that direct the metabolic activity of target cells. While each miRNA targets multiple messenger RNAs (mRNAs), which may coordinate or antagonize each other's functions, several miRNAs are dysregulated in other tissues during obesity-related comorbidities. Deletion of the miRNA-processing enzyme DICER in pro-opiomelanocortin-expressing cells results in obesity, which is characterized by hyperphagia, increased adiposity, hyperleptinemia, defective glucose metabolism, and alterations in the pituitary-adrenal axis. In recent years, RNA-based therapeutical approaches have entered clinical trials as novel therapies against overweight and its complications. Development of lipid droplets, macrophage accumulation, macrophage polarization, tumor necrosis factor receptor-associated factor 6 activity, lipolysis, lipotoxicity, and insulin resistance are effectively controlled by miRNAs. Thereby, miRNAs as epigenetic regulators are used to determine the new gene transcripts and therapeutic targets.

Indexed as

AdipogenesisEpigenesis, GeneticMicroRNAsObesityAdipocytesAnimalsExosomesGene Expression RegulationHumansMicroRNAsAdipocyte-derived microvesicles (ADMs)AdipogenesisAdiponectinCytidine-cytidine-adenosine-adenosine-thymidine (CCAAT)/enhancer-binding protein (C/EBP)Fatty acid binding protein 4 (FABP4)Forkhead box protein O1 (FoxO1)Insulin resistanceInterleukin 1 (IL-1) receptor-associated kinase-1 (IRAK-1)LeptinLipid dropletsLipotoxicityMicro-ribonucleic acid-103 (miR-103)Micro ribonucleic acid-143 (miR-143)Micro-ribonucleic acid-148a (miR-148a)Micro-ribonucleic acid-155 (miR-155)Micro-ribonucleic acid-221 (miR-221)Micro-ribonucleic acid-223 (miR-223)Micro-ribonucleic acid-33 (miR-33)Micro-ribonucleic acid-34 (miR-34)Micro-ribonucleic acids (miRNAs)ObesityOxidized low density lipoprotein (Ox-LDL)Peroxisome proliferator-activated receptor-gamma (PPAR-γ)Silent information regulator 1 (SIRT1)Sterol regulatory element-binding protein (SREBP)Toll-like receptor 4 (TLR4)TriglycerideTumor necrosis factor-alpha (TNF-α)Tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6)Weight loss

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.